Trial Profile
A Phase 1 Study Evaluating Safety, Tolerability, and Pharmacokinetics of Escalating Doses of AGS67E Given as Monotherapy in Subjects With Refractory or Relapsed Lymphoid Malignancies
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs AGS 67E (Primary)
- Indications Chronic lymphocytic leukaemia; Hairy cell leukaemia; Lymphoid leukaemia; Non-Hodgkin's lymphoma
- Focus Adverse reactions; First in man; Pharmacokinetics
- Sponsors Agensys; Astellas Pharma Global Development
- 05 Mar 2020 Status changed from active, no longer recruiting to completed.
- 29 Jul 2019 Planned End Date changed from 1 Jun 2019 to 1 Aug 2021.
- 29 Jul 2019 Planned primary completion date changed from 1 Jun 2019 to 1 Aug 2021.